» Articles » PMID: 750112

Effect of Various Substitutions in Positions 1, 2, 3, and 4 of 4-demethoxydaunorubicin and 4-demethoxyadriamycin

Overview
Specialty Oncology
Date 1978 Jan 1
PMID 750112
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies on structure-activity relationships of anthracycline antitumor antibiotics have shown that removal of the methoxyl group at position 4 of the aglycone causes a marked increase in the potency of the compounds: 4-demethoxydaunorubicin and 4-demethoxyadriamycin had an antitumor effect similar to that of the parent compound at doses five to eight times lower, and they were active even when administered orally. This paper reports the effects of further substitutions at positions 1, 2, 3, and 4 of 4-demethoxy aglycone. The introduction of methyl groups at positions 2 and 3, or 1 and 4 resulted in decreased cytotoxicity and biological activity. The addition of a benzoyl ring at positions 2 and 3 decreased the activity further. 1,4-Dichloro-4-demethoxydaunorubicin and 2,3-dichloro-4-demethoxydaunorubicin were respectively as active and 2.5 times less active than was daunorubicin against HeLa cells in vitro while they were inactive against P388 and L1210 leukemias in vivo. 2,3-Dimethyl-4-demethoxyadriamycin showed an antitumor activity against mouse leukemias that was slightly higher than was that of adriamycin.

Citing Articles

Evaluation of new anthracycline analogs with the human tumor stem cell assay.

Salmon S, Liu R, CASAZZA A Cancer Chemother Pharmacol. 1981; 6(2):103-9.

PMID: 6946877 DOI: 10.1007/BF00262325.


Synthesis, biological and biochemical properties of new anthracyclines modified in the aminosugar moiety.

Bargiotti A, CASAZZA A, Cassinelli G, Di Marco A, Penco S, Pratesi G Cancer Chemother Pharmacol. 1983; 10(2):84-9.

PMID: 6831630 DOI: 10.1007/BF00446215.


Mutagenic and cytotoxic activity of doxorubicin and daunorubicin derivatives on prokaryotic and eukaryotic cells.

Babudri N, Pani B, Tamaro M, Monti-Bragadin C, Zunino F Br J Cancer. 1984; 50(1):91-6.

PMID: 6378238 PMC: 1976926. DOI: 10.1038/bjc.1984.143.


Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors.

Formelli F, CASAZZA A, Di Marco A, Mariani A, Pollini C Cancer Chemother Pharmacol. 1979; 3(4):261-9.

PMID: 294954 DOI: 10.1007/BF00254742.

References
1.
Supino R, NECCO A, Dasdia T, CASAZZA A, Di Marco A . Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin. Cancer Res. 1977; 37(12):4523-8. View

2.
Barranco S, Novak J . Survival responses of dividing and nondividing mammalian cells after treatment with hydroxyurea, arabinosylcytosine, or adriamycin. Cancer Res. 1974; 34(7):1616-8. View

3.
ARCAMONE F, Penco S, Vigevani A, Redaelli S, Franchi G, DiMarco A . Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone. J Med Chem. 1975; 18(7):703-7. DOI: 10.1021/jm00241a013. View

4.
Di Marco A, CASAZZA A, Dasdia T, Giuliani F, Lenaz L, NECCO A . Cytotoxic, antiviral, and antitumor activity of some derivatives of daunomycin (NSC-82151). Cancer Chemother Rep. 1973; 57(3):269-74. View

5.
Zunino F, Gambetta R, Di Marco A, Zaccara A . Interaction of daunomycin and its derivatives with DNA. Biochim Biophys Acta. 1972; 277(3):489-98. DOI: 10.1016/0005-2787(72)90092-5. View